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Ethnopharmacological relevance: Aloysia gratissima (Verbenaceae) is an aromatic plant distributed in
South America and, employed in folk medicine for the treatment of nervous systems illness, including
depression. The neuroprotective and antidepressant-like activities of the aqueous extract of Aloysia
gratissima (AE) administered orally has already been demonstrated.In this study the involvement of
monoaminergic systems in the antidepressant-like effect of the AE was investigated.
Materials and methods: The implication of the monoaminergic systems in the antidepressant-like activity
of Aloysia gratissima was evaluated using different pharmacological antagonists that were administered
previously to the acute oral administration of AE (10 mg/kg). The antidepressant-like effect was assessed
in the TST and locomotor activity was evaluated in the open-ﬁeld test in mice.
Results: The anti‐immobility effect elicited by AE in the TST was prevented by the pre-treatment of mice
with the antagonists, NAN‐190 (5‐HT1A receptor), ketanserin (5‐HT2A/2C receptor), prazosin (α1‐adreno-
ceptor), yohimbine (α2‐adrenoceptor), SCH23390 (dopamine D1 receptor), or sulpiride (dopamine D2
receptor).
Conclusions: These results indicate that the antidepressant‐like effect of AE in the TST is dependent on its
interaction with the serotonergic (5‐HT1A and 5‐HT2A/2C), noradrenergic (α1 and α2−adrenoceptors) and
dopaminergic (D1 and D2 receptors) systems, suggesting that this specie might act as a new potential
resource for developing antidepressants to treat depressive disorders.
& 2013 Elsevier Ireland Ltd. All rights reserved.1. Introduction
Depression is a common disorder affecting over 120 million people
worldwide and recent epidemiological surveys conducted in general
populations have found that the lifetime prevalence of depression is
in the range of 10–15% (Lépine and Briley, 2011). In spite of the
introduction of the tricyclic antidepressants (TCAs), selective serotonin
reuptake inhibitors (SSRIs), monoamine oxidase inhibitors (MAOIs)
and speciﬁc serotonin–noradrenaline reuptake inhibitors (SNRIs),
depression continues to be a major medical problem. However,
antidepressant treatments largely have weaknesses such as slow
onset and severe side effects (Dhingra and Parle, 2012).
Because of these problems individuals are seeking alternatives
to pharmaceutical medications and herbal therapies may be
effective alternative therapeutic tools for the treatment of depres-
sion, as in the case of St. John's wort (Linde and Knüppel, 2005).d Ltd. All rights reserved.
: +55 47 3321 0231.
il.com (A.L.B. Zeni).The search for novel pharmacotherapy from medicinal plants for
depression has increased markedly over the past decades (Zhang,
2004; Sarris et al., 2011). Importantly, it is worth mentioning that
new potential treatments for depression seems to act through a
mechanism which does not differ signiﬁcantly with respect to that
of “classical” antidepressants such as inhibition of monoamine re-
uptake (such as serotonin, dopamine and noradrenaline), aug-
mentation of binding and sensitization of serotonin receptors,
inhibition of monoamine oxidase, and modulation of neuro-
endocrine system (Machado et al., 2007; Sarris et al., 2011).
Recently, the usage of traditional herbs has supported new
alternatives for the treatment of depression and there is a growing
abundance of preclinical and clinical studies which reveal a
range of complex psychotropic activity from herbal medicines poten-
tially beneﬁcial for treating certain psychiatric conditions, most
notably depression (Sarris et al., 2011). Therefore, the search for
new antidepressant drugs is urgent in exploring more promising
antidepressant although, the lack of wide scientiﬁc research involving
therapeutic potential, safety, and quality of herbal extracts (Calixto,
2005; Sarris et al., 2011) deserves immediate attention.
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belonging to the Verbenaceae family which is widely distributed
in subtropical regions of South America mainly Brazil, Paraguay,
and Argentina. Aloysia gratissima has been investigated for viruci-
dal (García et al., 2003), nematicidal (Duschatzky et al., 2004),
fungicidal (Dellacasa et al., 2003), antioxidant (Rosas-Romero
and Saavedra, 2005; Zeni et al., 2013), antibacterial, and antiede-
matogenic (Vandresen et al., 2010) activities and recently,
antidepressant-like and neuroprotective effects by our research
group (Zeni et al., 2011).
The ethnopharmacological purposes for Aloysia gratissima such
as headache, bronchitis, and nervous systems disorders including
symptoms related to depression, e.g., changes of humor and
sadness have been reported by several authors (Del Vitto et al.,
1997; Souza and Wiest, 2007; Vendruscolo et al., 2005; Arias
Toledo, 2009). Considering all information, this study was aimed at
extending the study with Aloysia gratissima by investigating a
possible participation of the monoaminergic systems in the
antidepressant-like effect of an acute administration of AE in the
tail suspension test (TST) in mice.2. Material and methods
2.1. Plant material and production of aqueous extract
Stems and leaves of Aloysia gratissima (Gill. et Hook) Tronc.
(Verbenaceae) were collected in Guabiruba, Santa Catarina, iden-
tiﬁed and authenticated taxonomically at Regional University of
Blumenau. A voucher specimen (Excicata number 2658) was
deposited in the Dr. Roberto Miguel Klein Herbarium for future
reference in Regional University of Blumenau, Santa Catarina,
Brazil. The procedure to obtain the aqueous extract from Aloysia
gratissima (AE) and phytochemical proﬁle were recently described
(Zeni et al., 2013). In summary, dried powdered material (2.5 g)
was extracted with boiling water (150 ml) for 5 min. The extract
obtained was lyophilized and stored and, suspended in distilled
water at the time of the administration (yield: 25.71%).
2.2. Animals
Swiss male mice (60–70 days old weighing 30–40 g) were
maintained at 22–23 1C with free access to water and food, under
a 12:12 h light: dark cycle (lights on at 7:00 h). All manipulations
were carried out between 9:00 and 16:00 h, with each animal
used only once. The experiments were performed after approval of
the protocol by the Ethics Committee of the Federal University of
Santa Catarina and all efforts were made to minimize animal
suffering.
2.3. Drugs and treatment
The following drugs were used: Ketanserin tartarate, 1-(2-
methoxyphenyl)-4[-(2-phthalimido)butyl]piperazine (NAN-190),
sulpiride, prazosin, yohimbine, (R)-(+)-7-chloro-8-hydroxy-3-
methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-enzazepinehydrochlor-
ide (SCH23390) (all from Sigma Chemical Company, St. Louis, MO,
U.S.A.). Drugs were dissolved in saline except NAN-190 that was
diluted in saline with 1% Tween 80. Sulpiride and prazosin were
diluted in saline with 5% dimethylsulfoxide (DMSO). Appropriate
vehicle-treated groups were also assessed simultaneously. All
drugs were administered by intraperitoneal (i.p.) route, except
SCH23390 that was administered by subcutaneous (s.c.) route.
The AE (10 mg/kg) was dissolved in distilled water and admi-
nistered acutely by oral route (p.o.) by gavage, 60 min before the
TST or the open-ﬁeld test. The dissolution of the extract wasfreshly done from the lyophilized powdered immediately before
its administration. A control group received equal volume of
distilled water.
To address some of the mechanisms by which the extract
causes antidepressant-like action in the TST, animals were treated
with different drugs. The experiments were performed to assess
the interaction of the extract with the monoaminergic system. For
that, mice were pre-treated with vehicle, NAN-190 (0.5 mg/kg, a 5‐
HT1A receptor antagonist), ketanserin (5 mg/kg, a 5-HT2A/2C recep-
tor antagonist), prazosin (1 mg/kg, an α1-adrenoceptor antagonist),
yohimbine (1 mg/kg, an α2-adrenoceptor antagonist), SCH23390
(0.05 mg/kg, a dopamine D1 receptor antagonist), or sulpiride
(50 mg/kg, a dopamine D2 receptor antagonist), and 30 min later
they received vehicle or extract (10 mg/kg, p.o.) before being
tested in the TST after 60 min, as described previously (Binfaré
et al., 2009; Machado et al., 2009).
2.4. Behavioral tests
2.4.1. Tail suspension test (TST)
The tail suspension test has become one of the most widely
used models for assessing antidepressant-like activity in mice. The
test is based on the fact that animals subjected to the short-term,
inescapable stress of being suspended by their tail, will develop an
immobile posture. The total duration of immobility induced by tail
suspension was measured according to the method described by
Steru et al. (1985). Brieﬂy, mice both acoustically and visually
isolated were suspended 50 cm above the ﬂoor by adhesive tape
placed approximately 1 cm from the tip of the tail. Immobility
time was recorded during a 6 min period. Mice were considered
immobile only when they hung passively and completely motion-
less. The immobility time was recorded by an observer blind to the
drug treatment (Rodrigues et al., 2002; Zeni et al., 2011).
2.4.2. Open-ﬁeld test
The ambulatory behavior was assessed in an open-ﬁeld test as
described previously (Rodrigues et al., 2002; Rosa et al., 2008). The
apparatus consisted of a wooden box measuring 406050 cm3
high. The ﬂoor of the arena was divided into 12 equal rectangles.
At the start of the each trial, a mouse was placed in the left corner
of the ﬁeld and was allowed to freely explore the arena. The
number of rectangles crossed with all paws (crossing) was counted
in a 6-min session. The light was maintained at minimum to avoid
anxiety behavior. The apparatus were cleaned with a solution of
10% ethanol between tests in order to hide animal clues.
The doses of the drugs used were selected on the basis of
literature and are previously reported not to increase locomotor
activity (Redrobe and Bourin, 1997; Kaster et al., 2005; Machado
et al., 2007; Binfaré et al., 2009).
2.5. Data analysis
Comparisons between treatment groups and control were
performed by two-way analysis of variance (ANOVA) followed by
Tukey's HSD test when appropriate. A value of Po0.05 was
considered to be signiﬁcant.3. Results
3.1. Involvement of the serotonergic system
The result presented in Fig. 1A shows that the pre-treatment of
mice with NAN‐190 (0.5 mg/kg, a 5‐HT1A receptor antagonist, i.p.)
on the anti-immobility effect of AE (10 mg/kg, p.o.) in the TST. The
pre-treatment of mice with NAN-190 was able to reverse the
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signiﬁcant differences of AE treatment [F(1,20)¼6.35, Po0.05]
and NAN-190 extract interaction [F(1,22)¼21.59, Po0.01], but
not NAN-190 pre-treatment [F(1,22)¼2.74, P¼0.11]. The adminis-
tration of NAN‐190 alone or in combination with AE did not affect
(P40.05) the ambulation in the open-ﬁeld test (Fig. 1B). Fig. 1C
shows the inﬂuence of pre-treatment of mice with ketanserin
(5 mg/kg, a 5-HT2A/2C receptor antagonist, i.p.) on the anti-
immobility effect of AE in the TST. A two-way ANOVA revealed
signiﬁcant differences of ketanserin pre-treatment [F(1,22)¼10.21,
Po0.01], AE treatment [F(1,22)¼4.80, Po0.05], and ketanser-
inAE interaction [F(1,22)¼14.05, Po0.01]. Post hoc analyses
indicated that the pre-treatment with ketanserin reversed the
decrease in immobility time produced by the AE in the TST. The
administration of ketanserin alone or in combination with AE did
not affect (P40.05) the ambulation in the open-ﬁeld (Fig. 1D).
3.2. Involvement of the noradrenergic system
Fig. 2A shows that the pre-treatment of mice with prazosin
(1 mg/kg, an α1-adrenoceptor antagonist, i.p.) prevented the
antidepressant-like effect of the AE (10 mg/kg, p.o.) in the TST.
The two-way ANOVA revealed signiﬁcant differences of prazosin
pre-treatment [F(1,20)¼25.67, Po0.01], extract treatment [F
(1,20)¼10.15, Po0.01], and prazosin pre-treatment extract
treatment interaction [F(1,20)¼25.88, Po0.01]. The administra-
tion of prazosin alone or in combination with AE did not affect
(P40.05) the ambulation in the open-ﬁeld (Fig. 2B). Fig. 2C shows
the effect of pre-treatment of mice with yohimbine (1 mg/kg, an
α2-adrenoceptor antagonist, i.p.) on the reduction in the immobi-
lity time elicited by the administration of AE (10 mg/kg, p.o.). The
pre-treatment of mice with yohimbine was able to reverse theFig. 1. Effect of the pre-treatment of mice with NAN-190 (0.5 mg/kg, i.p.) or ketanserin (5
kg, p.o.) in the TST, and the number of crossings in the open-ﬁeld test (panels B and D). E
the vehicle-treated control. #Po0.01 as compared with the extract alone.antidepressant-like effect of AE. A two-way ANOVA revealed
signiﬁcant differences of yohimbine pre-treatment [F(1,20)¼
10.75, Po0.01], AE treatment [F(1,20)¼18.08, Po0.01], and
yohimbine pre-treatmentAE treatment interaction [F(1,20)¼
27.30, Po0.01]. The administration of yohimbine alone or in
combination with AE did not affect (P40.05) the ambulation in
the open-ﬁeld (Fig. 2D).3.3. Involvement of the dopaminergic system
Fig. 3A shows that the anti-immobility effect of AE (10 mg/kg)
was signiﬁcantly prevented by pre-treatment of mice with
SCH23390 (0.05 mg/kg, a dopamine D1 receptor antagonist, s.c.).
A two-way ANOVA revealed signiﬁcant differences of SCH23390
pre-treatment [F(1,22)¼8.82, Po0.01] and extract treatment [F
(1,22)¼45.54, Po0.01], and SCH23390 pre-treatment extract
treatment interaction [F(1,22)¼5.18, Po0.05]. The administration
of SCH23390 alone or in combination with AE did not affect
(P40.05) the ambulation in the open-ﬁeld (Fig. 3B). The pre-
treatment of the animals with sulpiride (50 mg/kg, a D2 receptor
antagonist, i.p.) was also able to prevent the anti-immobility effect
of AE in the TST (Fig. 3C). The two-way ANOVA revealed signiﬁcant
differences of sulpiride pre-treatment [F(1,24)¼58.54, Po0.01],
extract treatment [F(1,24)¼22.77, Po0.01], and sulpiride pre-
treatment extract treatment interaction [F(1,24)¼42.78, Po
0.01]. Post hoc analyses indicated that the pre-treatment of mice
with SCH23390 and sulpiride prevented the decrease in immobi-
lity time in the TST produced by the administration of the extract.
The administration of sulpiride alone or in combination with AE
did not affect (P40.05) the ambulation in the open-ﬁeld (Fig. 3D).mg/kg, i.p., panels A and C, respectively) on the anti-immobility effect of AE (10 mg/
ach column represents the mean7S.E.M. of 6–7 animals. nnPo0.01 compared with
Fig. 2. Effect of the pre-treatment of mice with prazosin (1 mg/kg, i.p., panel A), yohimbine (1 mg/kg, i.p., panel C) on the anti-immobility effect of the aqueous AE (10 mg/kg,
p.o.) in the TST and the number of crossings in the open-ﬁeld test (panels B and D). Each column represents the mean7S.E.M. (n¼6). nnPo0.01 as compared with the
vehicle-treated control. #Po0.01 as compared with the extract alone.
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The monoaminergic hypothesis of depression postulates that
the major neurochemical process in depression is the impairment
of monoaminergic neurotransmission and the concomitant
decrease on extracellular concentration of noradrenaline and/or
serotonin (Schildkraut, 1965). Most of the prescribed antidepres-
sants inhibit serotonin or noradrenaline reuptake and/or mono-
amine oxidase inhibitors act by increasing the synaptic availability of
these neurotransmitters (Montgomery, 1999; Taylor and Stein, 2006).
The dopaminergic system is also an important target implicated in
the regulation of mood disorders (Dailly et al., 2004), as preclinical
and clinical studies have indicated a diminished dopamine turnover
in depression (Elhwuegi, 2004; Millan, 2004).
This study intends to expand previous analysis on the possible
mechanisms involved in the antidepressant-like effects of AE in the
TST, since the TST is a well-characterized behavioral model predictive
of antidepressant activity that is sensitive to antidepressants from
different pharmacological classes (Steru et al., 1985; Cryan et al.,
2005) and modulated by serotonergic, noradrenergic, and dopami-
nergic systems, among others (Cryan et al., 2005; O’Leary et al., 2007).
Aloysia gratissima has been reported to exhibit antidepressant-
like effect in the TST, which is mediated through of the inhibition
of the glutamatergic system (Zeni et al., 2011). Furthermore, the
major polyphenolic compound of Aloysia gratissima, ferulic acid
(Zeni et al., 2013), was also reported to produce an antidepressant-
like effect (Zhang et al., 2011; Zeni et al., 2012) dependent on the
serotonergic system. Of note, Poleszak et al. (2011) reported that
the interaction with serotonergic system is necessary for the on
antidepressant-like activity of glycine/NMDA site ligands.In this study, the involvement of monoaminergic systems in the
mechanism of AE antidepressant-like effect was assessed by
treating mice with several pharmacological antagonists in order
to investigate their inﬂuence on the anti-immobility action of AE
in the TST. The results indicate that the effect of AE in the TST was
reversed by pre-treatment of mice with the 5-HT1A antagonist,
NAN-190, suggesting the participation of 5-HT1A receptors in the
antidepressant-like effect of AE. Considering that Foong and
Bornstein (2009) showed that NAN-190 also blocks α2-adrenocep-
tors in the guinea pig, one possibility is that the ability of NAN-190
to abolish the antidepressant-like effect of AE may be due to, at
least in part, the involvement of α2-adrenoceptors. Pharmacologic
and genetic studies have demonstrated that the serotonergic
system plays a central role in the pathophysiology and etiology
of depression (Ansorge et al., 2007) and a major role in the action
of antidepressants (Millan, 2004). In accordance with Machado
et al. (2009) and Binfaré et al. (2009) the pre-treatment with the
NAN-190 also abolished the anti-immobility effect elicited by
Rosmarinus ofﬁcinalis L. or ascorbic acid, respectively.
The antidepressant-like effect of AE was also prevented by the
pre-treatment with ketanserin, a 5-HT2A/2C receptor antagonist.
Preclinical and clinical studies have reported a key role for 5-HT2
receptors in the pathology of depression, as well as the action of
many antidepressants (Cryan and Leonard, 2000; Boothman et al.,
2006). A similar result was reported in previous studies from our
research group in which ketanserin was able to reverse the
antidepressant-like effect in the TST of extracts from Schinus molle
L. (Machado et al., 2007), Rosmarinus ofﬁcinalis L. (Machado et al.,
2009), and Tabebuia avellanedae L. (Freitas et al., 2010). Thus, the
present study indicates that the antidepressant-like effect of the
Fig. 3. Effect of the pre-treatment of mice with SCH23390 (0.05 mg/kg, s.c., panel A), and sulpiride (50 mg/kg, i.p., panel C) on the anti-immobility effect of the AE (10 mg/kg,
p.o.) in the TST and the number of crossings in the open-ﬁeld test (panels B and D). Each column represents the mean7S.E.M. (n¼6–7) nnPo0.01 as compared with the
vehicle-treated control. #Po0.01 as compared with the extract alone.
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HT2C receptors.
The role of noradrenaline on the pathophysiology of depression
has been extensively investigated, since some antidepressant
drugs increase the synaptic concentration of noradrenaline and
they might act directly at noradrenergic receptors (Elhwuegi,
2004). Depression is associated with a hypofunction of the
noradrenergic system and some antidepressants such as noradre-
naline reuptake inhibitors or monoamine oxidase inhibitors act by
increasing the synaptic availability of noradrenaline (Montgomery,
1999; Taylor and Stein, 2006).
In our study, the pre-treatment of mice with prazosin (an α1-
adrenoreceptor antagonist) and yohimbine (an α2-adrenoreceptor
antagonist) was able to block the antidepressant-like effect of AE.
This result indicates that AE could exert its effect in the TST by
interacting with both α1 and α2-adrenoceptors. It has been
demonstrated that the pre-treatment of mice with prazosin was
also able to reverse the antidepressant-like effect of the extract of
Rosmarinus ofﬁcinalis (Machado et al., 2009) in the TST. In addition,
the antidepressant-like effects of Schinus molle (Machado et al.,
2007) or Tabebuia avellanedae (Freitas et al., 2010), as well as the
ascorbic acid in the TST (Binfaré et al., 2009) were reversed by the
α2-adrenoceptor antagonist yohimbine. Accordingly, there is com-
pelling evidence for the role of α1 and α2-adrenoceptors in the
mechanism of action of antidepressant agents as desipramine and
amitriptyline (Kitada et al., 1986; Millan, 2004).
In the present work we have also observed that the selective
dopamine D1 receptor antagonist SCH23390 and the dopamine D2
receptor antagonist sulpiride abolished the anti-immobility effects
of AE in the TST. Indeed, our results point to a participation of both
dopamine D1 and D2 receptors in the antidepressant-like effects ofthe extract investigated. This result is in agreement with the well-
known relationship between dopamine neurotransmission and
depression extensively reported in preclinical and clinical studies
(Elhwuegi, 2004; Millan, 2004). Depressed and/or suicidal patients
present reduced levels of dopamine and its metabolite homova-
nillic acid when compared to non-depressed ones (Hamner and
Diamond, 1996; Papakostas, 2006). Furthermore, ﬁndings indi-
cated that there is an increased dopamine D2/D3 receptor binding
(Klimek et al., 2002) and reduced dopamine transporter activity
(Meyer et al., 2001; Klimek et al., 2002) in depressive patients.
Additionally, reports suggest that severity of depression is inver-
sely correlated with central nervous system dopamine metabolite
levels (Papakostas, 2006).
Some studies have indicated that the dopamine D1 receptor
antagonist SCH23390 prevented the antidepressant-like effect of
some antidepressant agents in the FST and TST (Yamada et al.,
2004; Hirano et al., 2007). Furthermore, preclinical data indicate
that dopamine D2 receptors are related to the anti-immobility
action of antidepressants in the FST (Yamada et al., 2004). Thus,
our results suggest that the effect of AE in the TST may depend on
activation of both dopamine D1 and D2 receptors. It has been
demonstrated that pre-treatment of mice with prazosin was able
to reverse the antidepressant-like effect of the extract of Rosmar-
inus ofﬁcinalis (Machado et al., 2009). In addition, similar to our
results the antidepressant-like effects of Schinus molle (Machado
et al., 2007) and Tabebuia avellanedae (Freitas et al., 2010) were
reversed by SCH23390.
Drugs inhibiting the uptake of serotonin, noradrenaline, and
dopamine (triple reuptake inhibitors) that have been recently
developed could produce a more rapid onset of action and possess
greater efﬁcacy than traditional antidepressants (Chen and
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several herbal extracts and constituents as antidepressant agents,
whose mechanism of action involves a simultaneous interaction
with the monoaminergic systems (Rodrigues et al., 2002; Zhang,
2004; Machado et al., 2007, 2009; Binfaré et al., 2009; Freitas
et al., 2010). In this study, AE exerts antidepressant-like effect
through the involvement of serotonergic, noradrenergic and
dopaminergic systems. Indeed, ferulic acid, the major polyphenolic
compound of AE inhibits serotonin reuptake in hippocampus of
rats and it has been proposed that the inhibition of noradrenaline
and dopamine receptors is implicated in its anti-immobility effect
(Zhang et al., 2011).
Similar to the ﬁndings with ascorbic acid reported by Binfaré
et al., (2009) and Moretti et al. (2011), the present study has also
demonstrated that the administration of AE produced an
antidepressant-like effect in the TST. Therefore, both AE and
ascorbic acid act through a mechanism that is dependent on their
interaction with the monoaminergic systems, N-methyl-D-aspar-
tate (NMDA) receptors and the L-arginine–nitric oxide (NO)–cyclic
guanosine monophosphate (cGMP) pathway (Zeni et al., 2011).
Furthermore, an additional study aiming at clarifying the mechan-
ism of action by which AE induces antidepressant-like effect is
essential, such as, measuring the reuptake of monoamines or
activity on transporters.
The results herein shown reveal that AE is an effective
antidepressant-like complex matrix with meaningful effects on
the monoaminergic systems as well as on the L-arginine–NO
pathway, corroborating the folk medicine usage of that plant
species in southern Brazil.5. Conclusion
In conclusion, the present study provides additional evidence
indicating that the AE produces a speciﬁc antidepressant-like
effect in the TST through the interaction with the serotonergic
(5-HT1A and 5-HT2A/2C receptors), noradrenergic (α1 and α2-adreno-
ceptors) and dopaminergic (D1 and D2 receptors) systems. Thus, our
results suggest that AE shares with established antidepressants some
mechanisms of action. At least at a preclinical level the ﬁndings
reported here is a relevant contribution to validate the traditional use
of Aloysia gratissima.Acknowledgments
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